{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:31:47Z","timestamp":1769499107276,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T00:00:00Z","timestamp":1294272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1001043","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T22:19:55Z","timestamp":1294352395000},"page":"e1001043","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Novel Approach to Pharmacodynamic Assessment of Antimicrobial Agents: New Insights to Dosing Regimen Design"],"prefix":"10.1371","volume":"7","author":[{"given":"Vincent H.","family":"Tam","sequence":"first","affiliation":[]},{"given":"Michael","family":"Nikolaou","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2011,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.","volume":"44","author":"PG Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019.","volume":"2","author":"GL Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/14787210.3.3.361","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of anti-infective agents.","volume":"3","author":"EL Schuck","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref4","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro: a review.","volume":"Suppl 74","author":"WA Craig","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.49.9.3624-3630.2005","article-title":"Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.","volume":"49","author":"VH Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.42.5.1105","article-title":"Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.","volume":"42","author":"A Louie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.","volume":"45","author":"A Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1172\/JCI200316814","article-title":"Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.","volume":"112","author":"N Jumbe","year":"2003","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/AAC.48.2.369-377.2004","article-title":"Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.","volume":"48","author":"M Mueller","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00044011-199611040-00006","article-title":"Dosage Regimens of Antibacterials: Implications of a Pharmacokinetic\/Pharmacodynamic Model.","volume":"11","author":"MJY Bouvier d'Yvoire","year":"1996","journal-title":"Clin Drug Investig"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01165-05","article-title":"Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.","volume":"50","author":"VH Tam","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dki086","article-title":"Modelling time-kill studies to discern the pharmacodynamics of meropenem.","volume":"55","author":"VH Tam","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/AAC.01468-07","article-title":"Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.","volume":"52","author":"VH Tam","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/AAC.49.1.209-219.2005","article-title":"Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.","volume":"49","author":"JJ Campion","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/AAC.41.2.363","article-title":"The population dynamics of antimicrobial chemotherapy.","volume":"41","author":"M Lipsitch","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/AAC.41.4.733","article-title":"Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.","volume":"41","author":"JW Mouton","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/430611","article-title":"Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.","volume":"192","author":"VH Tam","year":"2005","journal-title":"J Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1086\/518003","article-title":"Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.","volume":"195","author":"VH Tam","year":"2007","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00285-005-0350-6","article-title":"A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations.","volume":"52","author":"M Nikolaou","year":"2006","journal-title":"J Math Biol"},{"key":"ref20","article-title":"ADAPT II: pharmacokinetic\/pharmacodynamic systems analysis software","author":"DZ D' Argenio","year":"1997"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jac\/dkp247","article-title":"Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.","volume":"64","author":"R Singh","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1007\/s10439-007-9306-x","article-title":"Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents.","volume":"35","author":"M Nikolaou","year":"2007","journal-title":"Ann Biomed Eng"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.","volume":"37","author":"A Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.","volume":"279","author":"SL Preston","year":"1998","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.","volume":"49","author":"A Louie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/424465","article-title":"Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.","volume":"190","author":"NP Wiederhold","year":"2004","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1128\/AAC.00922-07","article-title":"Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.","volume":"52","author":"KE Bowker","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.","volume":"49","author":"VH Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00003088-200544020-00005","article-title":"Pharmacokinetic\/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.","volume":"44","author":"JW Mouton","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10928-007-9069-x","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.","volume":"34","author":"D Czock","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10928-010-9151-7","article-title":"Basic PK\/PD principles of drug effects in circular\/proliferative systems for disease modelling.","volume":"37","author":"P Jacqmin","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1001043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:53:59Z","timestamp":1589021639000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1001043"}},"subtitle":[],"editor":[{"given":"Philip E.","family":"Bourne","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2011,1,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1001043","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,6]]}}}